« Back
Home /
Saracatinib

Saracatinib

Item no.	M1659-1g
Manufacturer	AbMole
CASRN	379231-04-6
Amount	1g
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Bladder Cancer Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	>99.0%
Citations	Src inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Simpkins, et al . Clin Cancer Res. 2012 Aug 15. PMID: 22896656 . Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo. Liu, et al . Int J Cancer. 2012 May 24. PMID: 22623106 . Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Arcaroli, et al . Clin Cancer Res. 2012 May 1,18(9):2704-14. PMID: 22553375 . Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours. Kaye, et al . Br J Cancer. 2012 May 22,106(11):1728-34. PMID: 22531637 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AZD0530
Similar products	Saracatinib, AZD0530
Available
Molecular Weight	542, 03
Solubility	DMSO 33 mg/mL
Bioactivity information	Saracatinib (AZD0530) is an orally active small molecule Src inhibitor.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1659-1g-safety-datasheet.pdf